Endothelial dysfunction and coronary artery disease: A state of the art review

Cardiology in Review

Volumn 23, Issue 3, 2015, Pages 119-129

  Veerasamy, Murugapathy ^a,b   Bagnall, Alan ^a,b   Neely, Dermot ^c   Allen, John ^a,b   Sinclair, Hannah ^a,b   Kunadian, Vijay ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

atherosclerosis; coronary artery disease; endothelial dysfunction

Indexed keywords

BIOCHEMICAL MARKER; CELL MARKER; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PROSTACYCLIN; THROMBOXANE A2;

ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIET; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; GENE THERAPY; HAND GRIP; HUMAN; LASER DOPPLER FLOWMETRY; LIFESTYLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL TONOMETRY; PHOTOELECTRIC PLETHYSMOGRAPHY; REGULATORY MECHANISM; REVIEW; SHEAR STRESS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; CORONARY BLOOD VESSEL; PHYSIOLOGY; VASODILATATION;

CORONARY ARTERY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; VASODILATION;

EID: 84936891272     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000047     Document Type: Review

References (156)

1. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk?. Circulation. 2002; 106: 640-642.
2. Lüscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997; 20(11 suppl 2): II-3-10.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809.
4. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002; 40: 505-510.
5. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653-658.
6. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-Term outcome of coronary heart disease. Circulation. 2000; 101: 1899-1906.
7. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-Term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948-954.
8. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001; 12: 383-389.
9. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med. 2003; 348: 1483-1485.
10. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006; 113: 1708-1714.
11. Teerlink T, Luo Z, Palm F, et al. Cellular ADMA: regulation and action. Pharmacol Res. 2009; 60: 448-460.
12. Stamler JS, Lamas S, Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell. 2001; 106: 675-683.
13. Corson MA, James NL, Latta SE, et al. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996; 79: 984-991.
14. Gimbrone MA Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol. 1999; 155: 1-5.
15. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001; 280: F193-F206.
16. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc. 1979; 38: 66-71.
17. Félétou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler Thromb Vasc Biol. 2006; 26: 1215-1225.
18. Busse R, Edwards G, Félétou M, et al. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002; 23: 374-380.
19. Chen G, Hashitani H, Suzuki H. Endothelium-dependent relaxation and hyperpolarization of canine coronary artery smooth muscles in relation to the electrogenic Na-K pump. Br J Pharmacol. 1989; 98: 950-956.
20. Sandow SL, Tare M, Coleman HA, et al. Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res. 2002; 90: 1108-1113.
21. Suga S, Nakao K, Itoh H, et al. Endothelial production of C-Type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest. 1992; 90: 1145-1149.
22. Wei CM, Hu S, Miller VM, et al. Vascular actions of C-Type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 1994; 205: 765-771.
23. Porter JG, Catalano R, McEnroe G, et al. C-Type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Physiol. 1992; 263(5 Pt 1): C1001-C1006.
24. Scotland RS, Ahluwalia A, Hobbs AJ. C-Type natriuretic peptide in vascular physiology and disease. Pharmacol Ther. 2005; 105: 85-93.
25. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989; 86: 2863-2867.
26. Yanagisawa M, Kurihara H, Kimura S, et al. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988; 6: S188-S191.
27. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br J Pharmacol. 2008; 153: 1105-1119.
28. Ellis EF, Oelz O, Roberts LJ 2nd, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science. 1976; 193: 1135-1137.
29. Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and disease. J Lipid Res. 2009; 50 suppl: S423-S428.
30. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995; 11: 376-381.
31. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-Activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23: 599-622.
32. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
33. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116: 1832-1844.
34. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004; 16: 42-47.
35. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardio5vascular biology and disease. Circ Res. 2000; 86: 494-501.
36. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108: 1912-1916.
37. Koppenol WH, Moreno JJ, Pryor WA, et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol. 1992; 5: 834-842.
38. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003; 111: 1201-1209.
39. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun. 1999; 263: 681-684.
40. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439-1441.
41. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913-919.
42. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003; 107: 1383-1389.
43. Slager CJ, Wentzel JJ, Gijsen FJ, et al. The role of shear stress in the generation of rupture-prone vulnerable plaques. Nat Clin Pract Cardiovasc Med. 2005; 2: 401-407.
44. Papaioannou TG, Karatzis EN, Vavuranakis M, et al. Assessment of vascular wall shear stress and implications for atherosclerotic disease. Int J Cardiol. 2006; 113: 12-18.
45. Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res. 1990; 66: 1045-1066.
46. Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007; 49: 2379-2393.
47. Chatzizisis YS, Baker AB, Sukhova GK, et al. Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation. 2011; 123: 621-630.
48. Stone PH, Saito S, Takahashi S, et al.; PREDICTION Investigators. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study. Circulation. 2012; 126: 172-181.
49. Widlansky ME, Gokce N, Keaney JF Jr, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003; 42: 1149-1160.
50. Tousoulis D, Davies G. Acetylcholine and endothelial function. Circulation. 1998; 98: 1588-1589.
51. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989; 83: 1946-1952.
52. Hess OM, Büchi M, Kirkeeide R, et al. Potential role of coronary vasoconstriction in ischaemic heart disease: effect of exercise. Eur Heart J. 1990; 11 (suppl B): 58-64.
53. Egashira K, Katsuda Y, Mohri M, et al. Role of endothelium-derived nitric oxide in coronary vasodilatation induced by pacing tachycardia in humans. Circ Res. 1996; 79: 331-335.
54. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation. 1990; 81: 850-859.
55. Beltrame JF, Crea F, Camici P. Advances in coronary microvascular dysfunction. Heart Lung Circ. 2009; 18: 19-27.
56. Melikian N, Kearney MT, Thomas MR, et al. A simple thermodilution technique to assess coronary endothelium-dependent microvascular function in humans: validation and comparison with coronary flow reserve. Eur Heart J. 2007; 28: 2188-2194.
57. Baumgart D, Haude M, Liu F, et al. Current concepts of coronary flow reserve for clinical decision making during cardiac catheterization. Am Heart J. 1998; 136: 136-149.
58. Kern MJ. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. Circulation. 2000; 101: 1344-1351.
59. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007; 356: 830-840.
60. Wilson RF, Marcus ML, White CW. Prediction of the physiologic significance of coronary arterial lesions by quantitative lesion geometry in patients with limited coronary artery disease. Circulation. 1987; 75: 723-732.
61. Hays AG, Hirsch GA, Kelle S, et al. Noninvasive visualization of coronary artery endothelial function in healthy subjects and in patients with coronary artery disease. J Am Coll Cardiol. 2010; 56: 1657-1665.
62. Mühling OM, Dickson ME, Zenovich A, et al. Quantitative magnetic resonance first-pass perfusion analysis: inter- and intraobserver agreement. J Cardiovasc Magn Reson. 2001; 3: 247-256.
63. Mühling OM, Wang Y, Jerosch-Herold M, et al. Improved myocardial function after transmyocardial laser revascularization according to cine magnetic resonance in a porcine model. J Thorac Cardiovasc Surg. 2004; 128: 391-395.
64. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med. 2005; 46: 75-88.
65. Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010; 3: 623-640.
66. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995; 26: 1235-1241.
67. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol. 2001; 52: 631-646.
68. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol. 2001; 38: 1106-1115.
69. Petrie JR, Ueda S, Morris AD, et al. How reproducible is bilateral forearm plethysmography?. Br J Clin Pharmacol. 1998; 45: 131-139.
70. Whitney RJ. The measurement of volume changes in human limbs. J Physiol. 1953; 121: 1-27.
71. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flowdependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995; 91: 1314-1319.
72. Joannides R, Richard V, Haefeli WE, et al. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension. 1995; 26: 327-331.
73. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients
74. Charakida M, Masi S, Lüscher TF, et al. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010; 31: 2854-2861.
75. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flowmediated dilation. Hypertension. 2010; 55: 1075-1085.
76. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011; 300: H2-H12.
77. Gori T, Dragoni S, Lisi M, et al. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol. 2008; 51: 1953-1958.
78. Gori T, Grotti S, Dragoni S, et al. Assessment of vascular function: flow-mediated constriction complements the information of flow-mediated dilatation. Heart. 2010; 96: 141-147.
79. Gori T, Parker JD, Münzel T. Flow-mediated constriction: further insight into a new measure of vascular function. Eur Heart J. 2011; 32: 784-787.
80. Gori T, Muxel S, Damaske A, et al. Endothelial function assessment: flowmediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. Eur Heart J. 2012; 33: 363-371.
81. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003; 146: 168-174.
82. Lavie P, Schnall RP, Sheffy J, et al. Peripheral vasoconstriction during REM sleep detected by a new plethysmographic method. Nat Med. 2000; 6: 606.
83. Nohria A, Gerhard-Herman M, Creager MA, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol (1985). 2006; 101: 545-548.
84. Noon JP, Haynes WG, Webb DJ, et al. Local inhibition of nitric oxide generation in man reduces blood flow in finger pulp but not in hand dorsum skin. J Physiol. 1996; 490 (pt 2): 501-508.
85. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44: 2137-2141.
86. Fredriksson I, Larsson M, Strömberg T. Measurement depth and volume in laser Doppler flowmetry. Microvasc Res. 2009; 78: 4-13.
87. Ozbebit FY, Esen F, Güleç S, et al. Evaluation of forearm microvascular blood flow regulation by laser Doppler flowmetry, iontophoresis, and curve analysis: contribution of axon reflex. Microvasc Res. 2004; 67: 207-214.
88. Agarwal SC, Allen J, Murray A, et al. Comparative reproducibility of dermal microvascular blood flow changes in response to acetylcholine iontophoresis, hyperthermia and reactive hyperaemia. Physiol Meas. 2010; 31: 1-11.
89. Kvandal P, Landsverk SA, Bernjak A, et al. Low-frequency oscillations of the laser Doppler perfusion signal in human skin. Microvasc Res. 2006; 72: 120-127.
90. Elgendi M. On the analysis of fingertip photoplethysmogram signals. Curr Cardiol Rev. 2012; 8: 14-25.
91. Zheng D, Allen J, Murray A. Non-invasive in vivo assessment of changes in peripheral arterial properties with estimation of arterial volume compliance. Physiol Meas. 2007; 28: 1317-1327.
92. Burger D, Touyz RM. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens. 2012; 6: 85-99.
93. Hart CM, Kleinhenz DJ, Dikalov SI, et al. The measurement of nitric oxide production by cultured endothelial cells. Methods Enzymol. 2005; 396: 502-514.
94. Nagababu E, Rifkind JM. Measurement of plasma nitrite by chemiluminescence. Methods Mol Biol. 2010; 610: 41-49.
95. Zeballos GA, Bernstein RD, Thompson CI, et al. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation. 1995; 91: 2982-2988.
96. Casey DP, Beck DT, Braith RW. Systemic plasma levels of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses in young men and women. Clin Exp Pharmacol Physiol. 2007; 34: 1291-1293.
97. Kelm M, Preik-Steinhoff H, Preik M, et al. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-Arginine-NO pathway. Cardiovasc Res. 1999; 41: 765-772.
98. Rassaf T, Heiss C, Hendgen-Cotta U, et al. Plasma nitrite reserve and endothelial function in the human forearm circulation. Free Radic Biol Med. 2006; 41: 295-301.
99. Saijo F, Milsom AB, Bryan NS, et al. On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease. Nitric Oxide. 2010; 22: 155-167.
100. Juonala M, Viikari L, Alfthan G, et al. Asymmetrical dimethylarginine is inversely associated with brachial flow-mediated dilation in young adults The cardiovascular risk in Young Finns Study. Atherosclerosis Supp. 2007; 8: 119.
101. Päivä H, Kähönen M, Lehtimäki T, et al. Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The cardiovascular risk in Young Finns Study. Atherosclerosis. 2010; 212: 512-515.
102. Sibal L, Agarwal SC, Schwedhelm E, et al. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol. 2009; 8: 27.
103. Teragawa H, Fukuda Y, Matsuda K, et al. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart. 2004; 90: 750-754.
104. Ferroni P, Guadagni F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets. 2008; 8: 194-202.
105. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009; 94: 3171-3182.
106. Yang P, Liu YF, Yang L, et al. Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clin Cardiol. 2010; 33: E81-E86.
107. Chironi GN, Boulanger CM, Simon A, et al. Endothelial microparticles in diseases. Cell Tissue Res. 2009; 335: 143-151.
108. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011; 31: 27-33.
109. Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab. 2006; 91: 3676-3679.
110. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol. 2008; 51: 1760-1771.
111. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006; 373: 17-26.
112. Lee KW, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol. 2006; 111: 302-308.
113. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593-600.
114. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 1998; 98: 211-216.
115. Schächinger V, Britten MB, Elsner M, et al. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation. 1999; 100: 1502-1508.
116. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990; 81: 491-497.
117. Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention: long-Term results from the Firefighters and Their Endothelium (FATE) study. Circulation. 2011; 123: 163-169.
118. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007; 115: 2390-2397.
119. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009; 120: 502-509.
120. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31: 1142-1148.
121. Vassanelli C, Menegatti G, Zanolla L, et al. Coronary vasoconstriction in response to acetylcholine after balloon angioplasty: possible role of endothelial dysfunction. Coron Artery Dis. 1994; 5: 979-986.
122. Caramori PR, Lima VC, Seidelin PH, et al. Long-Term endothelial dysfunction after coronary artery stenting. J Am Coll Cardiol. 1999; 34: 1675-1679.
123. Minami Y, Kaneda H, Inoue M, et al. Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature. Int J Cardiol. 2013; 165: 222-228.
124. Clarkson P, Montgomery HE, Mullen MJ, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol. 1999; 33: 1379-1385.
125. DeSouza CA, Shapiro LF, Clevenger CM, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation. 2000; 102: 1351-1357.
126. Higashi Y, Sasaki S, Kurisu S, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 1999; 100: 1194-1202.
127. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998; 98: 2709-2715.
128. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000; 342: 454-460.
129. Duffy SJ, Keaney JF Jr, Holbrook M, et al. Short- and long-Term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001; 104: 151-156.
130. Stein JH, Keevil JG, Wiebe DA, et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999; 100: 1050-1055.
131. Agewall S, Wright S, Doughty RN, et al. Does a glass of red wine improve endothelial function?. Eur Heart J. 2000; 21: 74-78.
132. Goodfellow J, Bellamy MF, Ramsey MW, et al. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000; 35: 265-270.
133. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001; 103: 799-805.
134. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996; 94: 258-265.
135. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007; 30: 1351-1356.
136. ODriscoll G, Green D, Maiorana A, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1999; 33: 1506-1511.
137. ODriscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997; 100: 678-684.
138. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153.
139. ODriscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126-1131.
140. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129-1135.
141. Matsuno H, Takei M, Hayashi H, et al. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol. 2004; 43: 333-340.
142. Lerman A, Burnett JC Jr, Higano ST, et al. Long-Term L-Arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998; 97: 2123-2128.
143. Bai Y, Sun L, Yang T, et al. Increase in fasting vascular endothelial function after short-Term oral L-Arginine is effective when baseline flow-mediated dilation is low: a meta-Analysis of randomized controlled trials. Am J Clin Nutr. 2009; 89: 77-84.
144. Jahangir E, Vita JA, Handy D, et al. The effect of L-Arginine and creatine on vascular function and homocysteine metabolism. Vasc Med. 2009; 14: 239-248.
145. Higashi Y, Sasaki S, Nakagawa K, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2002; 15(4 pt 1): 326-332.
146. Heitzer T, Krohn K, Albers S, et al. Tetrahydrobiopterin improves endothelium- dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia. 2000; 43: 1435-1438.
147. Maier W, Cosentino F, Lütolf RB, et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000; 35: 173-178.
148. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002; 22: 6-13.
149. Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003; 89: 990-995.
150. Tousoulis D, Antoniades C, Tentolouris C, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis. 2003; 170: 261-267.
151. Tousoulis D, Antoniades C, Stefanadis C. Statins and antioxidant vitamins: should co-Administration be avoided?. J Am Coll Cardiol. 2006; 47: 1237; author reply 1237.
152. Ye Y, Li J, Yuan Z. Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-Analysis of randomized controlled trials. PLoS One. 2013; 8: e56803.
153. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005; 1: 183-198.
154. Hayashi T, Sumi D, Juliet PA, et al. Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. Cardiovasc Res. 2004; 61: 339-351.
155. Sharif F, Hynes SO, Cooney R, et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther. 2008; 16: 1674-1680.
156. Sethi R, Lee CH. Endothelial progenitor cell capture stent: safety and effectiveness. J Interv Cardiol. 2012; 25: 493-500.